Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA

You may also be interested in...



Korea’s Dong-A Wins WHO Prequalification For TB Generic Of Lilly’s Seromycin As Firm Moves Up Value Chain

WHO prequalification clears path for Korea’s Dong-A to move from an API supplier of cycloserine to an exporter of finished products.

Korean Pharma Earnings Roundup: Dong-A, Green Cross Retain Leading Positions While Yuhan, LG Life, Hanmi Struggle

SEOUL - Of South Korea's five top pharmaceutical companies, Dong-A and Green Cross did relatively well in 2010, retaining their leading positions while Yuhan, LG Life Sciences and Hanmi failed to witness upward momentum amid a tightened government grip on the local pharmaceutical industry

Korea’s Bukwang To Sell Hepatitis B Drug In Philippines, Plans Launches In U.S., Europe   

SEOUL - South Korea's Bukwang Pharmaceutical will begin selling its chronic hepatitis B drug Levovir (clevudine) in the Philippines in June, and plans to eventually launch the product across Asia, the U.S. and Europe, according to a company executive

UsernamePublicRestriction

Register

ID1131161

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel